Form 4: ALX Oncology Holdings Inc. Director Jaume Pons Sells 20,000 Shares

Jaume Pons, President & CSO and Director of ALX Oncology Holdings Inc., sold 20,000 shares of common stock on April 4, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On April 4, 2024, Jaume Pons, a Director and the President & CSO of ALX Oncology Holdings Inc., sold 20,000 shares of the company's common stock.
• The shares were sold at a weighted average price of $11.1518, with individual prices ranging from $10.86 to $11.275.
• The sale was executed under a Rule 10b5-1 trading plan adopted on December 6, 2023.
• Following the transaction, Jaume Pons directly owns 628,359 shares of ALX Oncology Holdings Inc.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reports a routine stock sale by an insider under a pre-arranged trading plan. There is no indication of positive or negative implications for the company.

Industry Context

Sales by company insiders are a common occurrence and are closely watched by investors for signals about the company's prospects. A Rule 10b5-1 trading plan allows insiders to sell shares over a predetermined period, which can mitigate concerns about trading on non-public information.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders, potentially causing a slight decrease in stock price due to increased selling pressure.

Key Dates